PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types (Q38084846)

28 August 2017

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types (English)

1 reference

28 August 2017

Carolyn D Britten

1

1 reference

28 August 2017

27 February 2013

1 reference

Cancer Chemotherapy and Pharmacology

28 August 2017

1 reference

28 August 2017

71

1 reference

28 August 2017

6

1 reference

28 August 2017

1395-1409

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-013-2121-1

28 August 2017

0 references

cites work

Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

The PI3K pathway as drug target in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

The emerging mechanisms of isoform-specific PI3K signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Phosphatidylinositol-3-OH kinase as a direct target of Ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Phosphorylation and regulation of Raf by Akt (protein kinase B)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Targeting RAS signalling pathways in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Clinical experience of MEK inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Genetic predictors of MEK dependence in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Differences underlying EGFR and HER2 oncogene addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Ras in cancer and developmental diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Clinical correlates of NRAS and BRAF mutations in primary human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Rethinking ovarian cancer: recommendations for improving outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Triple negative breast cancer: unmet medical needs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Ocular toxicity of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2121-1

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/NATURE11156

Identifiers

DOI

10.1007/S00280-013-2121-1

1 reference

PubMed ID

23443307

Dimensions Publication ID

28 August 2017

0 references

1 reference

PubMed ID

23443307